Literature DB >> 10482551

Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.

R J Parks1, J L Bramson, Y Wan, C L Addison, F L Graham.   

Abstract

We have analyzed transgene (lacZ) expression from a first-generation adenovirus (Ad) vector in comparison to helper-dependent (hd) Ads deleted for various portions of the viral coding sequences and generated by using the Cre/loxP helper-dependent system (R. J. Parks et al., Proc. Natl. Acad. Sci. USA 93:13565-13570, 1996). An hd vector deleted for approximately 70% of the Ad genome (AdRP1001) provided levels and durations of transgene expression similar to those of a control first generation Ad vector containing an identical expression cassette. Deletion of all Ad sequences from the hdAd and replacement with a approximately 22-kb fragment of lambda DNA resulted in a decrease in the level and duration of lacZ expression which could not be reversed by the inclusion of a matrix attachment region. However, substitution of the lambda stuffer in the fully deleted hdAd with sequences from the human hypoxanthine-guanine phosphoribosyltransferase gene resulted in significantly improved transgene expression. In vitro assays for cytotoxic T lymphocytes (CTL) directed against putative peptides encoded by the vector backbone showed that, although CTL were generated against the vector containing the lambda DNA, no such CTL were generated against the vector containing the hypoxanthine-guanine phosphoribosyltransferase (HPRT) sequences. Surprisingly, the rate of loss of the HPRT- and lambda-containing vectors from mouse liver was similar, despite the differences in expression kinetics, indicating that the lambda stuffer-directed CTL were inefficient at eliminating the transduced cells. Thus, the nature of the DNA backbone of hdAds can have important effects on the functioning of the vector. Since most fully deleted vectors require "stuffer" DNA as part of the vector backbone to maintain optimum vector size, these observations must be taken into account in the design of hdAd vectors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482551      PMCID: PMC112818          DOI: 10.1128/JVI.73.10.8027-8034.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

Authors:  H L Davis; R Weeratna; T J Waldschmidt; L Tygrett; J Schorr; A M Krieg; R Weeranta
Journal:  J Immunol       Date:  1998-01-15       Impact factor: 5.422

2.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase.

Authors:  S Kochanek; P R Clemens; K Mitani; H H Chen; S Chan; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study.

Authors:  M J Goldman; L A Litzky; J F Engelhardt; J M Wilson
Journal:  Hum Gene Ther       Date:  1995-07       Impact factor: 5.695

Review 4.  The use of adenoviral vectors for gene therapy and gene transfer in vivo.

Authors:  J L Bramson; F L Graham; J Gauldie
Journal:  Curr Opin Biotechnol       Date:  1995-10       Impact factor: 9.740

5.  Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.

Authors:  M I Gorziglia; M J Kadan; S Yei; J Lim; G M Lee; R Luthra; B C Trapnell
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer.

Authors:  J T Vilquin; B Guérette; I Kinoshita; B Roy; M Goulet; C Gravel; R Roy; J P Tremblay
Journal:  Hum Gene Ther       Date:  1995-11       Impact factor: 5.695

7.  Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.

Authors:  K J Fisher; H Choi; J Burda; S J Chen; J M Wilson
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

8.  Characterization of an adenovirus gene transfer vector containing an E4 deletion.

Authors:  D Armentano; C C Sookdeo; K M Hehir; R J Gregory; J A St George; G A Prince; S C Wadsworth; A E Smith
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

9.  Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo.

Authors:  Y Yang; Z Xiang; H C Ertl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

10.  Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors.

Authors:  S K Tripathy; H B Black; E Goldwasser; J M Leiden
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  27 in total

1.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Molecular dissection of the inward rectifier potassium current (IK1) in rabbit cardiomyocytes: evidence for heteromeric co-assembly of Kir2.1 and Kir2.2.

Authors:  Carsten Zobel; Hee Cheol Cho; The-Tin Nguyen; Roman Pekhletski; Roberto J Diaz; Gregory J Wilson; Peter H Backx
Journal:  J Physiol       Date:  2003-06-06       Impact factor: 5.182

Review 4.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

5.  Activation of adenoviral gene expression by protein IX is not required for efficient virus replication.

Authors:  Kathy L Sargent; Robert A Meulenbroek; Robin J Parks
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 6.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

7.  Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression.

Authors:  P Joel Ross; Michael A Kennedy; Robin J Parks
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

8.  Assembly of helper-dependent adenovirus DNA into chromatin promotes efficient gene expression.

Authors:  P Joel Ross; Michael A Kennedy; Carin Christou; Milagros Risco Quiroz; Kathy L Poulin; Robin J Parks
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

9.  Impact of adenovirus life cycle progression on the generation of canine helper-dependent vectors.

Authors:  P Fernandes; D Simão; M R Guerreiro; E J Kremer; A S Coroadinha; P M Alves
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

Review 10.  Helper-dependent adenoviral vectors in experimental gene therapy.

Authors:  Alicja Józkowicz; Józef Dulak
Journal:  Acta Biochim Pol       Date:  2005-08-04       Impact factor: 2.149

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.